von Willebrand Factor: Biological function and molecular defects

被引:6
作者
Perutelli, P
Biglino, P
Mori, PG
机构
[1] Hematology Laboratory, Hematology and Oncology Department, G. Gaslini Children's Hospital, Genova
[2] Hematology Laboratory, Hematology and Oncology Department, G. Gaslini Children's Hospital, I-16147 Genova, L. go G. Gaslini
关键词
factor VIII; hemostasis; platelet membrane glycoproteins; von Willebrand disease; von Willebrand factor;
D O I
10.3109/08880019709030907
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The human von Willebrand factor (vWF) plays a pivotal role in the mechanisms of blood clotting and platelet thrombus formation; it also binds and stabilizes factor VIII procoagulant protein. The biological functions of vWF are dependent on distinct molecular domains responsible for the specificity and affinity for ligands. The multimeric structure of vWF provides an array of binding sites that allow multivalent interactions, thus supporting the formation of stable platelet aggregates at the site of vascular injury, particularly under flow conditions characterized by high shear stress. Quantitative and qualitative abnormalities of vWF cause the most common congenital bleeding disorder in humans, the von Willebrand disease (vWD). This review will provide an update on the recent advances toward the elucidation of structure-function relationships and the detection of molecular defects leading to vWD and will highlight the revised classification of vWD.
引用
收藏
页码:499 / 512
页数:14
相关论文
共 68 条
[1]   IDENTIFICATION OF ASPARTIC ACID-514 THROUGH GLUTAMIC ACID-542 AS A GLYCOPROTEIN-IB-IX COMPLEX RECEPTOR RECOGNITION SEQUENCE IN VONWILLEBRAND-FACTOR - MECHANISM OF MODULATION OF VONWILLEBRAND-FACTOR BY RISTOCETIN AND BOTROCETIN [J].
BERNDT, MC ;
WARD, CM ;
BOOTH, WJ ;
CASTALDI, PA ;
MAZUROV, AV ;
ANDREWS, RK .
BIOCHEMISTRY, 1992, 31 (45) :11144-11151
[2]  
BRIDGES AB, 1993, BRIT HEART J, V69, P121
[3]  
CHRISTOPHE O, 1994, BLOOD, V83, P3553
[4]   A MONOCLONAL-ANTIBODY (B724) TO VON-WILLEBRAND-FACTOR RECOGNIZING AN EPITOPE WITHIN THE A1 DISULFIDE LOOP (CYS509-CYS695) DISCRIMINATES BETWEEN TYPE 2A AND TYPE 2B VON-WILLEBRAND DISEASE [J].
CHRISTOPHE, O ;
ROUAULT, C ;
OBERT, B ;
PIETU, G ;
MEYER, D ;
GIRMA, JP .
BRITISH JOURNAL OF HAEMATOLOGY, 1995, 90 (01) :195-203
[5]   Comparative analysis of type 2b von Willebrand disease mutations: Implications for the mechanism of von Willebrand factor binding to platelets [J].
Cooney, KA ;
Ginsburg, D .
BLOOD, 1996, 87 (06) :2322-2328
[6]   FUNCTIONAL-ANALYSIS OF A TYPE-IIB VONWILLEBRAND DISEASE MISSENSE MUTATION - INCREASED BINDING OF LARGE VONWILLEBRAND-FACTOR MULTIMERS TO PLATELETS [J].
COONEY, KA ;
LYONS, SE ;
GINSBURG, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (07) :2869-2872
[7]   DISTINCT ABNORMALITIES IN THE INTERACTION OF PURIFIED TYPE-IIA AND TYPE-IIB VONWILLEBRAND-FACTOR WITH THE 2 PLATELET BINDING-SITES, GLYCOPROTEIN COMPLEX-IB-IX AND COMPLEX-IIB-IIIA [J].
DEMARCO, L ;
MAZZUCATO, M ;
DEROIA, D ;
CASONATO, A ;
FEDERICI, AB ;
GIROLAMI, A ;
RUGGERI, ZM .
JOURNAL OF CLINICAL INVESTIGATION, 1990, 86 (03) :785-792
[8]   LOCALIZATION OF VONWILLEBRAND-FACTOR BINDING DOMAINS TO ENDOTHELIAL EXTRACELLULAR-MATRIX AND TO TYPE-VI COLLAGEN [J].
DENIS, C ;
BARUCH, D ;
KIELTY, CM ;
AJZENBERG, N ;
CHRISTOPHE, O ;
MEYER, D .
ARTERIOSCLEROSIS AND THROMBOSIS, 1993, 13 (03) :398-406
[9]   HETEROGENEITY OF PLASMA VONWILLEBRAND-FACTOR MULTIMERS RESULTING FROM PROTEOLYSIS OF THE CONSTITUENT SUBUNIT [J].
DENT, JA ;
GALBUSERA, M ;
RUGGERI, ZM .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 88 (03) :774-782
[10]   IDENTIFICATION OF A CLEAVAGE SITE DIRECTING THE IMMUNOCHEMICAL DETECTION OF MOLECULAR ABNORMALITIES IN TYPE-IIA VONWILLEBRAND-FACTOR [J].
DENT, JA ;
BERKOWITZ, SD ;
WARE, J ;
KASPER, CK ;
RUGGERI, ZM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (16) :6306-6310